Free Access
Med Sci (Paris)
Volume 28, Number 1, Janvier 2012
Page(s) 44 - 46
Section Nouvelles
Published online 27 January 2012
  1. Hagberg B. Rett syndrome : clinical peculiarities and biological mysteries. Acta Paediatr 1995 ; 84 : 971–976. [CrossRef] [PubMed] [Google Scholar]
  2. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007 ; 56 : 422–437. [CrossRef] [PubMed] [Google Scholar]
  3. Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein2. Nat Genet 1999 ; 23 : 185–188. [CrossRef] [PubMed] [Google Scholar]
  4. Viemari JC, Roux JC, Tryba AK, et al. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci 2005 ; 25 : 11521–11530. [CrossRef] [PubMed] [Google Scholar]
  5. Han I, You Y, Kordower JH, et al. Differential vulnerability of neurons in Huntington’s disease: the role of cell type-specific features. J Neurochem 2010 ; 113 : 1073–1091. [PubMed] [Google Scholar]
  6. Caviston JP, Holzbaur EL. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 2009 ; 19 : 147–155. [CrossRef] [PubMed] [Google Scholar]
  7. McGuire JR, Rong J, Li SH, et al. Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J Biol Chem 2006 ; 281, 3552–3559. [CrossRef] [PubMed] [Google Scholar]
  8. Gauthier LR, Charrin BC, Borrell-Pagès M, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004 ; 118 : 127–138. [CrossRef] [PubMed] [Google Scholar]
  9. Chen WG, Chang Q, Lin Y, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003 ; 302 : 885–889. [CrossRef] [PubMed] [Google Scholar]
  10. Roux JC, Zala D, Panayotis N, et al. Modification of Mecp2 dosage alters axonal transport through the Huntingtin/Hap1 pathway. Neurobiol Dis 2012 ; 45 : 786–795. [CrossRef] [PubMed] [Google Scholar]
  11. Borrell-Pagès M, Canals JM, Cordelières FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006 ; 116 : 1410–1424. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.